Top 10 Companies in the Phosphorus‑32 Polycythemia Vera Myelosuppressive Therapy Market (2026): Market Leaders Powering Global Treatment

MARKET INSIGHTS

Phosphorus‑32 Polycythemia Vera Myelosuppressive Therapy Market size was valued at USD 28.5 million in 2025. The market is projected to grow from USD 29.4 million in 2026 to USD 42.7 million by 2034, exhibiting a CAGR of 4.8% during the forecast period.

Phosphorus‑32 is a beta‑emitting radioisotope utilized as a myelosuppressive agent in the management of polycythemia vera, a chronic myeloproliferative neoplasm characterized by excessive red blood cell production. This therapy works by selectively targeting rapidly dividing bone marrow cells, thereby reducing blood cell counts and alleviating symptoms associated with the disease. Administered intravenously, Phosphorus‑32 provides an effective option particularly for patients who are refractory or intolerant to standard treatments such as hydroxyurea, interferon, or phlebotomy.

The market experiences steady growth driven by the persistent need for alternative therapies in specific patient populations, especially elderly individuals over 70 years where Phosphorus‑32 retains clinical relevance. While newer targeted therapies like JAK inhibitors have expanded treatment options, Phosphorus‑32 continues to serve as a valuable myelosuppressive approach in select cases due to its ability to induce long‑term remissions. Factors supporting market expansion include rising prevalence of polycythemia vera, improved diagnostic capabilities leading to better patient identification, and ongoing recognition of its role when other modalities fail. However, the market remains niche given the preference for oral agents and concerns regarding long‑term risks such as leukemic transformation. Key manufacturers and radiopharmaceutical suppliers maintain established production and distribution networks to ensure availability of this specialized therapy globally.

Phosphorus‑32 Polycythemia Vera Myelosuppressive Therapy Market – View in Detailed Research Report

Top 10 Companies in the Phosphorus‑32 Polycythemia Vera Myelosuppressive Therapy Market

---

1. Nordion

Headquarters: Ottawa, Canada
Key Offering: High‑specific‑activity P‑32 production for myelosuppressive therapy

Nordion’s legacy in radioisotope manufacturing and its GMP‑certified cyclotron facility position it as the benchmark supplier for P‑32 worldwide. The company’s focus on quality assurance and streamlined logistics ensures consistent supply to oncology and hematology centres across North America and Europe.

Growth Initiatives:

• Expansion of cyclotron capacity to meet rising demand in emerging markets
• Collaboration with academic centres to refine dosing protocols
• Investment in digital tracking of radiopharmaceutical distribution

---

2. IBA

Headquarters: Brussels, Belgium
Key Offering: Customized P‑32 dosage forms and on‑site radiolabeling support

IBA’s integrated services allow clinicians to tailor treatment plans to individual patient risk profiles. By providing both production and on‑site support, IBA reduces logistical bottlenecks and enhances therapeutic precision.

Growth Initiatives:

• Development of nano‑encapsulated P‑32 formulations for targeted delivery
• Partnerships with European oncology networks to expand market reach
• Implementation of real‑time dose‑adjustment algorithms

---

3. Eckert & Ziegler

Headquarters: Erlangen, Germany
Key Offering: High‑purity P‑32 with value‑added radiopharmacy services

With a robust supply chain and a reputation for technical excellence, Eckert & Ziegler supplies P‑32 to a broad spectrum of hospitals and research institutions. Their focus on continuous quality improvement keeps the brand at the forefront of the market.

Growth Initiatives:

• Expansion of in‑house radiopharmacy units to support remote centres
• Collaborations with German universities for clinical trial support
• Investment in automation of radiolabeling processes

---

4. Radiopharm

Headquarters: Melbourne, Australia
Key Offering: P‑32 production and distribution across the Asia‑Pacific region

Radiopharm’s regional focus has enabled it to tap into a growing patient base in countries such as China and India. The company’s flexible manufacturing model supports rapid scale‑up in response to demand spikes.

Growth Initiatives:

• Partnership with local hospitals to streamline patient access
• Investment in regional cyclotron infrastructure
• Development of mobile radiopharmacy units for remote areas

---

5. JSR Radiation

Headquarters: Tokyo, Japan
Key Offering: P‑32 supply for high‑volume oncology centres

JSR Radiation’s strong presence in Japan’s advanced healthcare market provides a template for expansion into other Asian markets. Its focus on process optimisation has reduced lead times for radiopharmaceutical delivery.

Growth Initiatives:

• Collaboration with Japanese research institutes to explore combination therapies
• Expansion of regional distribution hubs
• Implementation of AI‑driven inventory management systems

---

6. Ciemat

Headquarters: Madrid, Spain
Key Offering: Domestic production of P‑32 with emphasis on cost‑efficiency

Ciemat’s domestic supply chain reduces dependence on international shipping, making P‑32 more accessible in Spain and surrounding European countries. The company’s focus on process standardisation supports consistent product quality.

Growth Initiatives:

• Investments in automated radiopharmaceutical synthesis
• Partnerships with Spanish oncology networks for clinical trials
• Development of low‑cost packaging solutions

---

7. Bhabha Atomic Research Centre (BARC)

Headquarters: Mumbai, India
Key Offering: P‑32 production tailored to Indian healthcare infrastructure

BARC’s integration of national research facilities with clinical supply chains positions it as a key player in India’s growing oncology market. The centre’s emphasis on research fosters continuous improvement of P‑32 therapeutic protocols.

Growth Initiatives:

• Expansion of domestic production capacity
• Collaborations with Indian hospitals for patient monitoring studies
• Development of low‑dose P‑32 formulations for elderly patients

---

8. GSI

Headquarters: Frankfurt, Germany
Key Offering: High‑purity P‑32 with advanced safety features

GSI’s focus on safety and quality control has earned it a strong reputation in the German market. The company’s investment in shielding technologies reduces radiation exposure for staff and patients alike.

Growth Initiatives:

• Development of radiation‑shielded delivery kits
• Partnerships with German clinical research institutes
• Expansion of service offerings to include patient education programmes

---

9. Radionuclide Therapeutics Ltd.

Headquarters: London, United Kingdom
Key Offering: P‑32 for oncology and hematology applications

Radionuclide Therapeutics Ltd. leverages its UK base to serve both domestic and European markets. The company’s emphasis on regulatory compliance ensures smooth market entry across multiple jurisdictions.

Growth Initiatives:

• Investment in cross‑border distribution networks
• Collaborations with UK cancer centres for clinical trials
• Development of patient‑friendly infusion protocols

---

10. AstraZeneca

Headquarters: Cambridge, United Kingdom
Key Offering: Exploration of P‑32 in combination with targeted therapies

AstraZeneca’s research pipeline includes studies on the synergistic effects of P‑32 with JAK inhibitors. The company’s global reach provides a platform for rapid dissemination of new therapeutic protocols.

Growth Initiatives:

• Clinical trials combining P‑32 with ropeginterferon alfa‑2b
• Partnerships with academic institutions for biomarker discovery
• Investment in patient‑centric care models

---

Download FREE Sample Report: Phosphorus‑32 Polycythemia Vera Myelosuppressive Therapy Market – View in Detailed Research Report

Get Full Report: Phosphorus‑32 Polycythemia Vera Myelosuppressive Therapy Market – View in Detailed Research Report

Outlook: The Future of Phosphorus‑32 Therapy

The market is evolving as clinicians balance the proven efficacy of P‑32 against emerging safety concerns. While the therapy remains a cornerstone for patients with limited options, its role is increasingly defined by precision dosing and integration with novel systemic agents.

Key Trends Shaping the Market

• Advances in imaging techniques allowing real‑time monitoring of marrow response
• Development of low‑dose P‑32 formulations tailored for elderly patients
• Emergence of combination protocols with JAK inhibitors to enhance efficacy
• Increased regulatory focus on radiation safety and waste management

Get Full Report: Phosphorus‑32 Polycythemia Vera Myelosuppressive Therapy Market – View in Detailed Research Report

The companies highlighted above are not only supplying P‑32 but are actively shaping the therapeutic landscape through research, innovation, and patient‑focused initiatives.